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1. Introduction
Hyperthyroidism is a syndrome characterised by the signs and symptoms of hyper-metabo‐
lism and excess sympathetic nervous system activity. It has an overall prevalence of 27 per
1000 women and 2.3 per 1000 men within the United Kingdom [1]. Hyperthyroidism occurs
as a result of either the excess synthesis or secretion of thyroid hormones by the thyroid gland
itself. It must be distinguished from thyrotoxicosis, in which excess thyroid hormone may
come from other sources, such as excess thyroid hormone ingestion, struma ovarii and
functional metastatic thyroid carcinoma[2,3].
Patients present with a variety of symptoms and clinical findings on physical examination. It
is important for clinicians to remember that these may be more subtle in the elderly population
who may present with fatigue or weakness, a condition known as apathetic hyperthyroidism,
or with predominantly cardiovascular signs such as atrial fibrillation, ischaemic heart disease
and congestive cardiac failure [4,5]. The routine use of serum thyrotropin (TSH) as a screening
investigation may allow earlier identification and treatment of the disease [6,7]. Radiological
imaging with iodine-123 uptake scanning and thyroid scintigraphy may aid in the identifica‐
tion of the underlying cause [6].
The management of hyperthyroidism is based on three treatment modalities, namely anti-
thyroid medication, radioactive iodine ablation or surgery. Patient, physician and geograph‐
ically preferences may dictate the choice of therapy. Given the overall healthcare costs of
hyperthyroidism, surgical intervention performed with minimal morbidity in high volume
centres may offer the highest chance of success with the lowest chance of recurrence [8].
The aim of this chapter is to discuss the role of surgical intervention in hyperthyroidism. Firstly,
to examine the evidence supporting surgical intervention in the management of Graves’
disease and that of toxic nodular goitres including toxic multi-nodular goitre and solitary toxic
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nodule. Secondly, and perhaps more controversially, the evidence for the extent of surgical
intervention in hyperthyroidism will be discussed focusing specifically on the evidence for
total compared with subtotal thyroidectomy.
2. Surgical anatomy
The thyroid gland is derived from the median thyroid diverticulum at the floor of the pharynx.
The thyroglossal duct extends from the foramen caecum at the base of the tongue to the isthmus
and is derived from the stalk of the diverticulum, which is later obliterated, with the distal
portion forming the pyramidal lobe of the thyroid. The ultimobranchial bodies that arise from
the fourth pharyngeal pouch become related to the lateral aspect of the gland and constitute
the para-follicular and C cells, which produce calcitonin [9,10,11].
The thyroid gland consists of two lobes connected by an isthmus that is situated antero-lateral
to the trachea and cricothyroid muscle. The gland itself has a bi-lobed shape and weighs 15 –
25g often depending on age and sex. Superiorly, the pyramidal extension (lobe) of the gland
may be found on the anterior surface of the cricothyroid. Laterally, the tubercles of Zucker‐
kandl, which arise from median anlage and ultimobranchial fusion, may form significant
protrusions of thyroid tissue within the tracheo-esophageal groove. Inferior to the thyroid lie
the thyrothymic rests. These occur in up to 50% of individuals and are classified according to
their connection to the thyroid [12).
The blood supply to the thyroid is derived from two main arteries; the superior thyroid artery,
which is a branch of the external carotid artery, and the inferior thyroid artery, which is a
branch of the thyrocervical trunk that itself is a branch of the subclavian artery. The main
venous drainage is through the middle thyroid vein directly into the internal jugular vein.
Other venous drainage includes the paired superior thyroid veins and a plexus of veins
draining the inferior poles of the gland. The lymphatic drainage is to local lymph nodes
situated in the central neck compartment and subsequently to cervical nodes [10,11].
The recurrent laryngeal nerve (RLN) and the external branch of the superior laryngeal nerve
(EBSLN) are closely related to the thyroid gland and can be vulnerable to damage during
thyroid surgery. An intimate knowledge of their anatomy in the neck is crucial to safe thyroid
surgery. The recurrent laryngeal nerve (RLN) originates from the vagus (X Cranial nerve)
nerve. The right RLN branches from the vagus as it crosses the subclavian artery and loops
around it, while the left nerve arises at the level of the arch of aorta and loops under it. Both
nerves lie and ascend in the tracheo-oesophageal groove, where they pass deep to the postero-
medial surface of the thyroid lobes [10,11]. The angle of the nerve relative to the trachea is
usually more oblique on the right. The nerve subsequently enters the larynx by passing behind
the inferior constrictors, supplying all the intrinsic muscles of the larynx except the cricothy‐
roid and sensation to the mucosa below the vocal cords [10,11]. The right RLN may have a
non-recurring course (0.3%) and derive directly from the vagus, approaching the cricothyroid
directly without travelling in the tracheo-esophageal groove. This occurs as a consequence of
a displaced right subclavian arterial takeoff from the aortic arch and may be identified pre-
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operatively if cross-sectional imaging is performed. Both left and right RLNs may give multiple
branches to the oesophagus and trachea. The RLN may bifurcate prior to insertion into the
cricothyroid, with the majority of the motor fibres being carried in the anterior portion of the
nerve [9,10,11].
The superior laryngeal nerve (SLN) also emanates from the vagus and travels deep and medial
to the carotid arteries where it then divides into an internal and external branch above the
superior horn of hyoid [all books Grays]. The internal branch travels in relation to the superior
laryngeal vessels and supplies the mucosa to the level of the vocal cords. The external branch
supplies the cricothyroid muscle and lies deep to superior thyroid artery [10], where it can be
particularly vulnerable to damage. In an attempt to minimise trauma to the EBSLN numerous
classifications have been proposed, the most widely adopted being that devised by Cernea et
al [13,14]. Type 1 EBSLN is where the EBSLN crosses the superior thyroid artery (STA) greater
than 1cm above the upper pole of the thyroid. It is the commonest (40 – 62%) type and suggests
that the nerve may not be significantly at risk. In type 2a and b, the EBSLN crosses the artery
less than 1 cm above the upper pole and may therefore be at risk during dissection [13,14].
Kierner et al proposed that these be further divided into type 3 EBSLN where the nerve crosses
the STA under the cover of the thyroid gland and type 4 is where the EBSLN had descended
dorsal to the artery and only crosses the branches of the STA immediately above the upper
pole of the thyroid [14].
The paired inferior and superior parathyroid glands are derived from the third and fourth
pharyngeal  pouches  respectively  and are  closely  related to  the  thyroid  in  position.  The
majority of individuals (85%) will have four glands while approximately 13% will have five
glands and an even smaller proportion will have greater than this. The superior gland is
found in over 90% of cases within 1cm of the junction of the inferior thyroid artery and
the recurrent laryngeal  nerve on the posterior aspect  of  the middle third of  the thyroid
gland.  The  inferior  parathyroid  glands,  in  conjunction  with  the  thymus,  have  a  longer
migration path and their location is therefore more variable. The majority will be found on
the anterior or postero-lateral aspect of the thyroid lobe or within the thyrothymic tract and
are typically symmetrical in location [9,10,11].
3. Hyperthyroidism
Hyperthyroidism, a disorder of the thyroid gland, arises as a result of either excess hormone
synthesis or secretion [2,3]. It has a population prevalence of 2% for women and 0.2% for men
[1]. It is common with the incidence of new cases in the UK per year among women being
reported at 3 per 1000 [6]. The mean age of diagnosis is 48 years with an increasing incidence
with age [6,15]. Grave’s disease, being the most common cause of hyperthyroidism, accounts
for 60-80% of all cases [16]. Other causes include hyperthyroidism resulting from a toxic
nodular goitre (single or multiple nodule) and these constitute the remaining 5-15% of all
causes. [16].
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Hyperthyroidism must be distinguished from thyrotoxicosis, which is defined as the excess
of circulating thyroid hormones in the bloodstream [17]. Causes for thyrotoxicosis vary and
include excess thyroid hormone ingestion, struma ovarii and functional metastatic thyroid
carcinoma [18]. These will not be discussed further in this chapter
4. Clinical features
Hyperthyroidism has a multi-system effect on the body, giving rise to a range of classic signs
and symptoms which are caused by increased catabolism [19]. Patients present with nervous‐
ness, fatigue, palpitations, heat intolerance, polyphagia and weight loss [6,9]. It is important
to note that the elderly may present with a different range of symptoms and exhibit more subtle
signs [20]. Weight loss and anorexia are common symptoms in older patients and may be
mistaken for the presence of a neoplastic process which can lead to over investigation [21].
As a result of the increased basal metabolic rate patients often present with a persisting
tachycardia. This occurs characteristically during sleep and may be associated with palpita‐
tions [22]. In the elderly and in those with pre-morbid cardiac disease, cardiac arrhythmias
may develop on this background [22]. Atrial fibrillation is the commonest arrhythmia and is
present in up to 20% of patients [18]. Interestingly, up to 15% of new onset atrial fibrillation in
the elderly population is due to hyperthyroidism [23]. This may be resistant to medical
treatment and resolves only when the underlying hyperthyroidism itself is treated [24].
Cardiovascular mortality is increased in hypertoxic states primarily as a result of ischaemic
heart disease and congestive heart failure [25,26].
Increasing dyspnoea may occur in hyperthyroid patients, limiting exercise tolerance. This is
thought to be due to a reduction in respiratory muscle mass and strength with a corresponding
reduction in the vital capacity [18]. Bone turnover is also increased in the thyrotoxic state due
to the direct stimulation of osteoclasts and osteoblasts to increase bone resorption [27,28]. Low
TSH levels, of themselves, have also been implicated in the dysregulation of bone turnover
[29]. Longstanding thyrotoxicosis can lead to increase bone loss and subsequent osteoporosis.
Thyrotoxic patients can be emotionally labile and restless. Other less common complaints
include poor concentration and changes in personality[3]. Overt psychosis, although rare may
occur [7].
5. Diagnosis
5.1. Biochemical
Serum thyrotropin (TSH) is the most commonly used screening test to diagnose hyperthyr‐
oidism with levels being low or undetectable [2]. TSH levels are measured using immunora‐
diometric and chemiluminescent methods which have a high sensitivity (100%) and specificity
(99.1%) [30,31]. When an abnormally low TSH is detected, free Thyroxine (T4) and free Tri-
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iodothyronine (T3) levels are measured to determine the degree of hyperthyroidism. Indirect
assays measure the free T4 and T3 level while sensitive and specific radioimmunoassays are
used to measure total T4 and T3 levels [7]. The presence of a low TSH with normal T4 and T3
level is defined as sub-clinical hyperthyroidism [32]. Atrial fibrillation, other cardiac arrhyth‐
mias and cardiovascular mortality are all associated with prolonged sub-clinical hyperthyr‐
oidism, especially in the elderly [33,34]. The identification of a normal T4 but a high free T3 is
known as T3 Thyrotoxicosis and may be an early manifestation of Grave’s disease [3,35].
The measurement of auto antibodies, thyroglobulin, thyroxine peroxidase (TPO) and TSH
receptor (TSHR) antibodies, may help in elucidating the underlying aetiology [6]. More than
90% of patients with Graves’ disease have increased levels of circulating TSHR antibodies and
in the setting of thyrotoxicosis it can confirm the diagnosis [3]. Similarly, TPO antibodies are
also present in approximately 75% of patients with Graves’ disease [2].
5.2. Radiological imaging
Radionuclide scanning and radioactive iodine uptake assesses the activity within the thyroid
gland and may be used as an adjunct to biochemical analysis to identify the underlying
aetiology of hyperthyroidism. Lesions are classified into three main categories: hot, whereby
there is hyper-accumulation of radiotracer; warm, where there is increased uptake with
suppression of background thyroidal tissue; or cold where the thyroid nodule is non-func‐
tioning [36]. Warm and hot nodules represent an increase in thyroid tissue turnover and may
therefore suggest a benign toxic cause (Figure 1). Cold nodules, on the other hand are con‐
cerning for malignancy and should proceed to an ultrasound and FNAC [36,37]. Typically in
Graves’ disease, thyroid tissue is diffusely hyper-active with increased radio-tracer throughout
the gland. In toxic nodular goitres, the radioactive iodine is focally concentrated in the nodules
with suppression of the background tissue giving patchy uptake [38].
Early radionuclide scans were performed using radioactive iodine. This had been subsequent‐
ly replaced by technetium (Tc-99m) pertechnetate. This has been shown to mimic the behaviour
and uptake of iodine within the thyroid gland but involves a much lower dose of radioactivity
and is cheaper [39].
Thyroid ultrasound has a limited role in patients with hyperthyroidism. It has been recom‐
mended to assess thyroid nodules, palpable thyroid abnormalities, nodular goitres and lesions
found incidentally by other imaging modalities [37]. However, in the presence of a low TSH
and a discrete hot nodule fine needle aspiration cytology should be avoided. Suspicious
nodules on ultrasound or cold nodules should be subjected to a FNAC to allow for a cytological
diagnosis to be made pre-operatively [37,38].
Chest radiography, CT and MRI scans can help in surgical planning for patients with com‐
pressive or obstructive symptoms although it is rarely used. CT scanning may allow assess‐
ment of size and extent of the goitre, including the presence of a retro-sternal component but
predominantly aids in pre-operative assessment of the airway (narrowing and displacement)
and the need for an awake fiber-optic intubation (Figure 1). When undertaking cross-sectional
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imaging, contrast should be avoided due to the high iodine content, which may acutely worsen
or induce symptoms of hyperthyroidism [40].
 
   
                (a)          (b) 
Figure 1. (a) Solitary nodule (b) Retrosternal extension of a large multinodular goitre
6. Aetiology of hyperthyroidism
6.1. Graves’ disease
Graves’ disease is an autoimmune disorder with a familial predisposition first described by
Robert James Grave in 1835 [41]. Overall the incidence of the disease is approximately 100-200
cases per 100,000 per year with a marked female predominance and accounts for approxi‐
mately 60–80% of all causes of hyperthyroidism [1,16]. A strong family history among affected
patients suggests a genetic predisposition however the incidence in monozygotic twins is
approximately 20% suggesting that penetrance is not 100% and other environmental causes
may play a role in pathogenesis [3,42]. It is typically associated with other autoimmune
conditions such as rheumatoid arthritis, SLE, Sjogrens, Type 1 Diabetes Mellitus and perni‐
cious anaemia [43]. Graves’ disease is also closely associated with myasthenia gravis occurring
in 3-5% of patients [18].
Graves’ disease classically consists of a triad of hyperthyroidism with diffuse goitre, oph‐
thalmopathy and pretibial myxoedema [44]. Each of these may run an independent course.
The clinical presentation includes signs and symptoms of thyrotoxicosis, a symmetrically
enlarged non tender goitre often with a palpable thrill or audible bruit [5]. However, it may
also present with a variable degree of extra-thyroidal manifestations such as ophthalmopathy,
pretibial myxoedema and acropachy [6]. Ophthalmopathy, proptoisis, extra-ocular muscle
involvement and rarely optic nerve compression, are thought to arise as a result of an immune
response to antigens within the retro-orbital tissues that are shared with the thyroid leading
to oedema and glycosaminoglycan deposition and fibrosis of the retro-orbital tissues [45,46].
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The diagnosis of Graves’ disease is made by establishing the presence of hyperthyroidism, the
presence of TSH auto-antibodies and diffuse increased symmetrical uptake on radio-iodine
scanning [47].
Treatment options include anti-thyroid medication, radioactive iodine ablation or surgical
intervention. The aim of treatment is to achieve a euthyroid state and in the presence of
ophthalmopathy to ensure overall stability. The ultimate decision regarding optimal manage‐
ment is tailored to an individual patient.
 
               
Figure 2. Graves opthalmopathy
6.2. Toxic nodular goitre
Toxic nodular disease, resulting from either multiple or single adenomatous nodules was first
described as a separate entity to Graves’ disease in 1913 by Henry Plummer [48]. Toxic nodular
goitre includes two distinct entities, toxic multi-nodular goitre and a solitary toxic nodule, also
known as Plummers’ Disease. Both are characterised by abnormal thyroid function independ‐
ent of TSH regulation. Together, they account for the second commonest cause of hyperthyr‐
oidism but there are differences in their pathogenesis and treatment and therefore will be
considered separately.
Toxic Multi-nodular Goitre
Toxic multinodular goitre is defined as a thyroid gland with two or more autonomously
functioning nodules [49]. It’s incidence ranges from 5% of all hyperthyroid cases in iodine
replete areas to 50% in iodine deficient areas and typically presents in older females [19]. Many
aetiological factors are involved in the pathogenesis of toxic multi-nodular goitre including
the functional heterogeneity of the thyroid follicles, the effects of growth factors and goitro‐
gens, the presence or absence of iodine and genetic abnormalities. Concurrent autoimmune
diseases are uncommon [50].
Patients present with less severe symptoms of hyperthyroidism and the onset may be more
insidious [51]. Typically they have compressive symptoms from an enlarging multi-nodular
goitre with retro-sternal extension [3]. The diagnosis is confirmed with a combination of
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biochemistry and radio-iodine scanning. Nuclear medicine scanning may show a heteroge‐
nous gland with mixed areas of hyper and hypo-activity [3,32]. Thyroid auto-antibodies are
negative. [32].
The treatment of multinodular goitres is aimed at eradication of all autonomously functioning
thyroid tissue. Given the concurrent compressive symptoms surgery may provide the most
definitive treatment. Recurrence of disease is more common with either medical anti-thyroid
medication or radio-iodine ablation [6,32].
Solitary Toxic Nodule
A solitary toxic nodule is an autonomously hyper-functioning nodule present within an
otherwise normal thyroid gland. Approximately 50% of solitary nodules are truly solitary,
while typically it presents as part of a nodular gland constituting a dominant nodule [52]. The
prevalence of palpable nodules in a population ages 30-59 years can be up to 4.2% [53].
Patients present with a neck lump, visible or palpable. Appropriate investigation of a solitary
nodule is crucial as the risk of malignancy is higher than in the presence of a multi-nodular
goitre [37]. The incidence of malignancy in truly solitary nodules is 5-15%, but this figure would
increase for solid or cold nodules to more than 25% [37]. Surgery remains the treatment of
choice for these patients although they may be observed if asymptomatic.
Treatment Options
The management of hyperthyroidism is based on three different treatment modalities, namely
anti-thyroid medication, radioactive iodine ablation or surgery. Patient, physician and
geographical preferences will dictate the choice of therapy. The overall aim of treatment is to
provide symptom relief, achieve a euthyroid state and to prevent recurrence. Given the overall
healthcare costs of hyperthyroidism, surgical intervention performed with minimal morbidity
in high volume centres may offer the highest chance of success with the lowest chance of
recurrence [8]. However, a prospective study by Torring et al examining such outcome
measures as patient satisfaction, time to euthyroidism and rates of sick leave demonstrated
equivalence between all three treatment modalities [54].
6.3. Anti thyroid drugs
Anti-thyroid medication is used to render patients euthyroid to either induce long-term
remission or as preparation for definitive treatment with radioactive ablation or surgery [2].
The main thioamide agents used are Carbimazole, Methamimazole and Propylthiouracil
(PTU). By inhibiting thyroxine peroxidase and interfering with both the organification of
iodide and the coupling of iodo-thyryronines a reduction in hormone synthesis is achieved
[6,55]. Initial doses of medication are usually high and a euthyroid state can be achieved after
8-12 weeks of treatment whereupon doses can be titrated downwards to a maintenance dose
[2]. PTU is preferred in pregnancy as at it less likely to cross the placenta due to protein binding
[56,57]. Treatment may be discontinued after one year if sustained remission is achieved with
the patient being euthyroid and TSH-R antibodies undetectable [19]. Remission can be variable
with reported relapse rates of between 50% to 60% [19]. Factors influencing relapse include
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smoking, compliance with medication, the presence of a large goitres and the elevated TSH-
R antibodies at end of treatment [58]. Side effects range from mild symptoms of urticaria, fever
and rash to more serious neutropenia, hepatotoxicity and vascultitis [55,59,60]. Agranulocy‐
tocis occurs in approximately 0.1-0.5% of treated patients and the rate of development of
hypothyroidism is 0.6% per annum [61,62]..
6.4. Radio-iodine ablation
Radio-iodine (RAI) can be used as first line treatment or for patients who have either failed
medical management or present with recurrent disease following a sub-total thyroidectomy.
Within the USA RAI is the first line treatment for patients with Graves’ disease [55]. Iodine-131
is taken up by the thyroid cells causing local apopotosis and subsequent fibrosis of the gland
thereby reducing the overall functional thyroid mass [22]. RAI is most suitable for patients
with a small goitre in the absence of ophthalomopathy. A wide variety of dosages (200–
600MBq) can be used [22]. The dosage however depends on the size and activity of the gland,
associated failure rates with low doses and the increased rate of hypothyroidism when higher
doses are utilised [19,63]. Absolute contra-indications include pregnancy, breastfeeding and
coexisting differentiated thyroid cancer [55]. RAI is usually avoided in patients with severe
ophthalmopathy as in approximately 15% of patient symptoms may worsen following
treatment [64,65]. It may be used cautiously in patients with stable eye disease in combination
with high dose glucocorticoids. [65].
Anti-thyroid agents are given for four to six weeks prior to radio-ablation in an attempt to
render patients euthyroid and thus prevent the development of a thyrotoxic crisis during initial
treatment [2]. These are discontinued two to three days prior to treatment to ensure functional
thyroid tissue which is required to take up iodine [2,66]. The majority of patients (75%) require
only a single dose of radio-iodine [67]. The effects of the RAI are not immediate and continue
for months following treatment. Symptomatic improvement can take up to two months.
Immediate complications include thyroid gland tenderness [32]. Long-term complications
include the development of hypothyroidism in approximately 60% of patients at 1 year, and
therefore regular long-term surveillance is warranted with T4 replacement as necessary [68].
6.5. Surgery
Surgery provides high cure rates in hyperthyroidism with minimal morbidity in high volume
centres It gives almost immediate relief of the compressive symptoms of large goitres, achieves
euthyroidism rapidly and consistently, and avoids the long term risks of radioactive iodine
and anti-thyroid medications [69]. Surgical intervention is warranted where the disease has
proved refractory to medical management, including both anti-thyroid medication and radio-
active iodine. Other indications for surgery include large goitres with compressive symptoms,
where RAI is contra-indicated including pregnancy (usually performed in the 2nd trimester)
and severe ophthalomopathy, desire for pregnancy soon after treatment, suspicion or presence
of underlying thyroid malignancy, for children and patient preference [5]
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Historically thyroid surgery was rarely performed for indications other than cancer until the
last quarter of the twentieth century [70]. The high peri-operative and post-operative morbidity
and mortality made the procedure untenable and indeed in 1850 it was banned by the French
Academy of Medicine [71]. However improvements in anti-sepsis, anaesthesia and the
introduction of anti-thyroid medication to render patients euthyroid pre-operatively revolu‐
tionised thyroid surgery. It is now well established as an acceptable and efficacious form of
treatment and the controversy focuses on the extent of intervention; sub-total versus total
thyroidectomy.
Currently, total thyroidectomy is regarded as the surgical procedure of choice for Graves’
disease, multi-nodular toxic and non toxic nodules [70,72-74]. A study by Efermidou et al
reviewing 932 cases of total thyroidectomy for benign thyroid disease showed that surgery
is  safe  and  is  associated  with  minimal  morbidity.  Patients  achieved  immediate  and
permanent  cure  with  no  risk  of  disease  recurrent  or  repeated  surgery  [75].  This  was
supported by Ballentone et al who demonstrated in over 500 patietns a postoperative rates
of haemorrhage of 1.5%, a permanent RLN palsy of 0.4% and a permanent rate of hypocal‐
caemia of 3.4%[76]. There was no recurrences noted during ther follow-up of 44 months
(Ballintone). Another study by Pappalardo et al randomised 141 patients into receiving a
total thyroidectomy or subtotal thyroidectomy and patients were followed up for a median
of 14.5 months. The rate of goitre recurrence in the subtotal thyroidectomy group was higher
at 14% [77].
Finally, a meta-analysis which included 1402 patients from 5 continents demonstrated higher
relapse rates with anti-thyroid drugs than radioactive iodine (52.7% vs 15%) and with anti-
thyroid drugs than surgery (52.7% vs 10%). In addition, examination of 31 scohort studies
which included 5136 patinets found an adverse effect rate of 13% in patients treated with anti-
thyroid drugs [78].
It is now widely accepted that high surgical volume in specialised units provides better patient
outcome. A systematic review published in the British Journal of Surgery in 2007 examined
1075 studies and found that high volume surgeons had better outcomes in 75% of the studies
and that specialised surgeons had significantly better outcomes than general surgeons in 91%
of the studies [79]. The association between volume and outcome has also been demonstrated
in thyroid surgery. Boudourakis et al performed a cross sectional analyses of a number of
surgeries deemed to have demonstrated a volume-outcome relationship. There was a signifi‐
cant increased in number of procedures performed by high volume surgeons during the study
period (23% for thyroidectomies). Unadjusted mortality and length of stay was significantly
lower for high-volume surgeons compared with low-volume surgeons [80]. In a study by
Pieracci et al, substernal thyroidectomy was compared with cervical thyroidectomy, with the
main aim of assessing outcomes (all volume type hospitals were included). Increasing hospital
volume predicted a decreased likelihood of overall complications, post-operative bleeding,
blood transfusion, respiratory failure, mortality and length of stay [81].
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7. Extent of surgery
7.1. Graves
Historically, a subtotal thyroidectomy was the procedure of choice in Graves’ disease,
minimizing the complications of surgery with potential cure of the disease. However, a
randomized trial comparing anti-thyroid drugs, radioiodine treatment, and surgery in Graves’
disease found all are equally effective in normalizing serum thyroid hormone concentrations
within six weeks and over 95% of the patients were satisfied with their therapy [54].
The type of surgery in Graves’ disease remains controversial. A total thyroidectomy ensures
complete cure of symptoms but is obviously associated with surgical hypothyroidism and the
need for lifelong thyroxine treatment. Conversely, subtotal thyroidectomy, given that a
proportion of thyroid tissue is left in-situ is associated with a higher likelihood of recurrence
and may still be associated with hypothyroidism. In a randomized trial of subtotal versus total
thyroidectomy for Graves’ disease involving 191 patients followed over five years, recurrent
hyperthyroidism occurred in 4.7% of patients after subtotal versus 0% after total thyroidecto‐
my, while transient hypoparathyroidism was seen in 6.8% and 12.6% respectively, and
permanent hypoparathyroidism in 0% and 0.5% respectively confirming the advantages of
total thyroidectomy without adversely affecting morbidity [82]. A meta-analysis published by
Palit et al demonstrated in 35 studies with over 7241 patients that the rates of RLN injury and
permanent hypo-parathyroidism were similar between subtotal and total thyroidectomy.
More importantly they also demonstrated an 8% recurrence risk in those patients who had a
subtotal thyroidectomy versus none in the total thyroidectomy group [83]. A further rando‐
mised trial published in the same year added weight to the call for total thyroidectomy as it
failed to demonstrate a significant difference in the complication rates between a total or
subtotal thyroidectomy [84]. Therefore total thyroidecomy should be considered the gold
standard surgical intervention in Graves’ disease.
7.2. Toxic multinodular goitre
Surgical resection remains the treatment of choice especially in the presence of a large goitre
and compressive symptoms where surgery gives prompt relief [85]. The extent of surgical
intervention and the comparative results of performing a near total or total thyroidectomy
have been topical in the last decade. Attempts to perform more minimal surgery have been
proposed to minimise the complications, such as RLN damage and permanent hypoparathyr‐
oidism, of thyroid surgery but are typically associated with higher rates of recurrence and an
increased requirement for re-operative surgery. Stenmuller et al showed that a lobectomy plus
a contralateral subtotal resection (known as the Dunhill procedure) and bilateral subtotal
resection resulted in a low overall incidence of permanent hypoparathyroidism and RLN
injury [86]. Rayes et al perfomed a prospective randomised study on 200 patients and con‐
cluded both can be performed with similar complication rates [87]. Remnant size was found
to determine recurrence rates. Barczynski et al compared total thyroidectomy, Dunhill
procedure and bilateral subtotal resection in 570 patients. Recurrence rates were 0.5% 4.7%
and 11.6% respectively with recurrence highest in bilateral subtotal resection. However this
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study also shows that although recurrence rates differ, reoperation rates for these recurrences
are comparable showing that not all of these recurrences may be clinically significant and
require further surgery [88]. Several other papers have also supported the role for total
thyroidectomy for multinodular goitre showing that it completely eradicates the disease
process, lowers the local recurrence rate, allows for avoiding the substantial risk of reoperative
surgery, and involves only a minimal risk of morbidity [89,90-91].
7.3. Toxic solitary nodule
For patients with a solitary toxic adenoma without evidence of nodules in the contralateral
lobe, a thyroid lobectomy is adequate. For patients with toxic adenoma and a coexisting
nonfunctioning nodule in the contralateral lobe, total thyroidectomy may be warranted
especially if there is any suspicion regarding thyroid malignancy. The main advantages of
surgery include immediate resolution of hyperthyroidsim symptoms, relief from compressive
symptoms, avoidance of radiation exposure to normal tissue and confirmation of diagnosis in
rare cases of suspected carcinoma [40]. The reported incidence of hypothyroidism is low (14%
with surgery compared with 22% with radioiodine treatment [40].
8. Preparation for surgery
Historically the mortality and morbidity associated with thyroid surgery was extremely high,
not only from intra-operative complications but from post-operative hormonal dysregulation
[92,93]. Meticulous pre-operative preparation of hyperthyroid patients has reduced this to less
that 1% in high volume centres [92,94].
8.1. Anti-thyroid drugs
The aim of preoperative preparation as previously discussed is to render patients as close as
possible to being clinically and biochemically euthyroid [22]. Antithyroid drugs interfere with
the incorporation of iodine into tyrosine residues and prevent the coupling of iodotyrosines
into iodothyronines [55]. Anti thyroid agents such as Carbimazole and Propythiouracil are
prescribed to achieve a euthyroid state [93,95]. The last dose should be given the day prior to
surgery [22].
8.2. Beta-blockers
Many manifestations of hyperthyroidism relate to the cardiovascular system and to the
sensitisation of the B-adrenergic receptors to catecholamines in patients who are thyrotoxic.
Pre-operative treatment with a beta-blocker such as propranolol controls adrenergic effects
[93]. It has also been shown to reduce the peripheral conversion of T4 to T3 [96]. Beta-blockers
are used in combination with antithyroid drugs and play an important role in pre-operative
patient preparation [97]. It is crucial to note that this drug should not be omitted on the morning
of surgery and must be continued for at least 5 days postoperatively [22]. Beta-blockers are
contraindicated in asthmatics, where a cardio-selective B-blocker may be considered [3].
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8.3. Iodine treatment
The use of iodines in the pre-operative management of Graves disease was first documented
in 1923 and its introduction saw a significant reduction in the mortality associated with thyroid
surgery [98]. Iodines are now routinely used in the peri-operative management of hyperthy‐
roid patients [93]. It is prescribed in the form of oral Lugol’s iodine (drops) at a dose of 24mg
divided over three doses administered 7–10 days pre-operatively to reduce the vascularity of
the gland [93]. It has been postulated that organic iodide such as Lugol’s solution usage can
decrease the vascularity of the thyroid gland pre-operatively by inhibiting vascular endothelial
growth factor A expression in thyroid follicles [99]. A randomised control trial by Erbil et al
using colour flow Doppler ultrasonography, immunohistochemical and western blot analysis
to compare thyroid vascularity with or without preoperative Lugol’s solution in 36 patients.
It showed a decrease in rate of blood flow to thyroid, thyroid vascularity and intra-operative
blood loss in the preoperative Lugol solution treatment group. They concluded that preoper‐
ative Lugols treatment reduces intraoperative bleeding which in turn improves the safety
profile of the procedure [100].
Large doses of iodine act by producing a transient remission of hormone synthesis by ‘stun‐
ning’ the thyroid gland an effect known as the Wolff-Chaikoff effect. It is a phenomenon where
higher than normal doses of iodine inhibit organification of thyroid hormone resulting in a
decrease in hormone synthesis and release [101]. Onset of action begins 24 hours post admin‐
istration peaking at approximately 10 days [102]. This can be seen as an auto-regulatory system
in dealing with supra-physiologic levels of iodine [93]. In normal euthyroid subjects thyroid
synthesis normalises due to down-regulation of the sodium iodine symporter known as the
escape phenomenon [103].
However, in hyperthyroid patients the escape phenomenon does not occur and Jod-Basedow
phenomenon occurs instead [93]. The Jod Basedow effect occurs due to dysregulation of iodine
in hyperthyroid patients where excess iodine stimulates more hormone production by acting
as the substrate [104]. It can result in a temporary hyperthyroidism, worsening of existing
hyperthyroidism or rarely a permanent rise in thyroid hormone [93]. Therefore iodines should
be used cautiously and for a limited time period in conjunction with anit-thryoid medication
in the pre-operative period.
9. Surgical intervention
9.1. Anaesthesia
The majority of thyroid surgery is performed under general anaesthetic without neuromus‐
cular blockade using an endotracheal cuffed tube to allow for intra-operative neuromonitor‐
ing. Local anasethic is given pre-operatively along the incision to ensure minimal post-
operative discomfort. In selective patients with small thyroid nodules and favourable anatomy
local anaesthetic has been documented as being utilised. Local anesthetic techniques require
the use of cervical block anesthesia. The disadvantage of this is risk of bilateral paralysis of the
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recurrent laryngeal nerve resulting from blockade with the local anaeasthetic, with consequent
difficulty in breathing postoperatively [105].
9.2. Intra-operative nerve monitoring
The primary complication of thyroid surgery is damage to either the recurrent laryngeal nerve
or the external branch of the superior laryngeal nerve. Routine visual identification of the RLN
decreases the incidence of injury and is standard practice (Figure 3). However, a recent survey
of members of the American Association of Endocrine Surgeons found that 63% of respondents
do not use neuromonitoring, 14% of surgeons used it routinely and 23% were selective users
[106]. Non-users were in practice longer, reported a lower case volume, were less familiar with
the technology and had limited access to the equipment [106].
The main role for intra-operative monitoring is to identify the RLN nerve, to aid in safe
dissection once it is identified and for prognostication of neural function postoperatively [107].
The two main components of monitoring are stimulation of the RLN and assessment of the
vocal cord response to stimulation. Several techniques have been described and are in routine
use. The most common method is the use of a laryngeal surface electrode which is applied to
the surface of the endotracheal tube in a proximal location to the vocal cord [108,109]. An
attached probe is used to deliver the low voltage electric current. During thyroid resection an
auditory signal or visual EMG signal can be used to provide information about the presence
and course of the RLN.
A systematic review of the literature demonstrated that neuromonitoring of the RLN during
thyroid surgery reduced RLN injury compared with routine nerve identification [110]. Other
studies comparing intra-operative nerve monitoring have demonstrated a benefit for its use
although a statistically significant difference between the groups could not be identified [111,
112]. A randomized trial of 1000 patients showed a decrease in transient but not permanent
RLN paresis compared to visualization alone [113]. In addition, there are studies which show
low sensitivity and positive predictive value of intra-operative neuromonitoring for predicting
nerve injury [114]. Despite this evidence, monitoring, when used appropriately, has been
shown to be feasible, safe and reproducible and should be considered for all cases. It must be
noted that neuromonitoring does not replace adequate intra-operative visualization and
meticulous surgical technique.
10. Surgical procedures in hyperthyroidism
10.1. Dunhill and Holtz procedures
Hartely and Dunhill described the procedure of subtotal thyroidectomy where a total thyroid
lobectomy is performed on one side and a small remnant is left in situ (weighing approximately
4 grams) on the contralateral side [5]. However it has been consistently difficult to assess the
residual remnant thyroid size and it may vary between 2–12 gms. The surgery is performed
through a collar incision placed halfway between the sternal notch and the thyroid cartilage.
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As the thyroid gland is approached, the middle thyroid vein is identified and ligated. The
entire lobe and isthmus are excised on the diseased side. On the contralateral side, the superior
pole is freed by dividing the superior vessels and the remaining thyroid lobe is approached
from a postero-lateral plane through the thyroid tissue leaving a posterior remnant. This keeps
the dissection plane away from the parathyroid glands and the recurrent laryngeal nerve on
this sub-total operative side [115].
The Enderlen Holtz procedure involves performing a subtotal bilateral thyroidectomy. The
procedure is similar to the Dunhill procedure and involves mobilisation of the thyroid gland
supero-laterally. In this case remnant tissue of 2 grams or more are left on both sides. Disad‐
vantages of both these procedures, as previously discussed include the high risk of recurrence
as well as an increased rate of complications (RLN damage and permanent hypoparathyroid‐
ism) associated with re-operative surgery [115].
10.2. Total thyroidectomy
The patient is positioned supine on the operating table in a slight reverse Trendelenburg
position. A gel pad or sand bag is placed transversely under the shoulders and the neck is
extended  and  placed  in  a  head  ring.  This  allows  the  thyroid  gland  to  become  more
prominent and applies tension to the skin, platysma, and strap muscles aiding in dissec‐
tion. In a total thyroidectomy complete excision of the gland, including the pyramidal lobe
is performed [22,105].
A curved incision is made midway between the suprastenal notch and the thyroid cartilage.
The incision is deepened through the skin, subcutaneous tissue and platysma. Skin flaps are
then raised upwards to the thyroid notch and downwards to the suprasternal notch. The deep
cervical fascia is then divided in the midline down and in-between the strap muscles to the
plane of the thyroid gland. The strap muscles are then retracted laterally and mobilised off the
Figure 3. Nerve stimulator used for intra-operative recurrent laryngeal nerve monitoring
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thyroid gland using an advanced surgical sealing instrument, such as the Ligasure vessel
sealing device (Covidien) [22,105].
The middle thyroid vein is encountered laterally, and this drains directly into the internal
jugular vein. This is ligated and divided. The plane between the medial pole of the upper
lobe and the cricothyroid muscle is subsequently developed, ensuring close proximity to
the  thyroid  in  order  to  avoid  trauma  or  injury  to  the  external  branch  of  the  superior
laryngeal nerve.  The branches of the superior thyroid artery are then ligated and divid‐
ed,  allowing  downward  delivery  of  the  upper  pole.  Capsular  dissection  is  then  per‐
formed and this invovles commencing the lateral component of the dissection high on the
surface  of  the  thyroid  gland,  diviging only  the  tertiary  branches  of  the  inferior  thyroid
artery and progressing posteriorly. In this process, the vascular supply of the parathyroid
glands is often well preserved [22,105,117].
The recurrent laryngeal nerve is identified in its course in the tracheo-esophageal groove. This
is first identified and sought below the level of the inferior thyroid artery, where it passes
obliquely upwards and forwards. The tubercle of Zuckerkandl serves as a useful landmark in
the identification of the RLN. Situated on posterolateral aspect of the gland in the tracheo-
esphageal groove in proximity of the cricothryoid membrane it is a constant landmark for RLN
identification which is aided by further mobilisation of the thyroid. The nerve is followed
upwards until it passes into the larynx under the inferior border of the inferior constrictor
behind the inferior cornu of the thyroid cartilage. In cases where the right nerve is difficult to
Figure 4. Thryoid gland and pyramidal lobe [116]
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identify one must consider an anomalous (non-recurrent) nerve, which is pesent in 1 percent
of patients. A non-recurrent RLN passes behind the carotid sheath and curves medially,
forwards and upwards and can be mistaken for the inferior thyroid artery. It is important to
be careful with diathermy and newer advanced sealing devices as heat conduction may
damage the RLN, the blood supply to the parathyroid’s or to the delicate areas within the
larynx [22,105,117].
The parathyroid glands must be identified in all cases. This is done by careful inspection of
the common locations and by utilising capsular dissection they can be peeled away from the
thyroid gland itself. Care is taken not to damage the branches of the inferior thyroid artery
which supply the parathyroid glands. If a parathyroid gland is accidentally excised or
Figure 5. Marking of incision
Figure 6. Mobilisation of the thyroid
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devascularised inadvertantly then it should be fragmented into small pieces and auto-
transplanted immediately within the sternocleidomastoid muscle [22,105,117].
Figure 7. Postero-lateral aspect of the thyroid
The pretacheal and cercval fascia are closed using interrupted sutures. Routine drain place‐
ment after thyroid surgery is not necessary. A meta-analysis of 11 randomized clinical trials
showed no significant difference in the incidence of hematoma or seroma between routine
drainage and no drainage [118]. If the thyroid is very large with a significant retrosternal
component or the dissection is extensive,a closed-suction drain can be placed to prevent a
serous fluid collection [118]. This can be removed safely when the drain output is serous and
decreasing in volume.
10.3. Thyroid lobectomy
Thyroid lobectomy is predominantly the treatment of choice in the management of solitary
toxic nodules because it not only removes the stimulus of excess thyroid production, but it also
allows definitive histological assessment of the nodule.
The details of the procedure, patient positing and exposure are similar to that of a total
thyroidectomy, as described above. In a thyroid lobectomy, the isthmus is transected using a
haemostatic device such as the harmonic scalpel or Ligasure [22,105,116].
10.4. Subtotal thyroidectomy
The thyroid gland is exposed in a similar manner to a total thyroidectomy. The middle thyroid
vein is encountered upon retractionof the strap muscles and is ligated and divided. The
superior poles of the thyroid are then ligated taking care to avoid the EBSLN [22,105,116]. The
inferior thyroid artery is identified and ligated lateral to the recurrent laryngeal nerve. The
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procedure then entails dividing across each lobe of the thyroid from the lateral edge towards
the trachea, leaving intact a posterior capsule with the attached remnant of the thyroid. For
ease of closure the thicker remnant of the gland is left laterally and incised more on the medial
aspect. This allows the folding over of the remnant laterally to medially, allowing the capsular
edges to be sutured together using a Vicryl suture. As a general guide the remnant strip is
often recommended to be 3cm x 1cm on each side. This operation is rarely used in modern
surgical practice [22,105,116].
Figure 8. Identification of recurrent laryngeal nerve
10.5. Surgery in recurrent thyroid disease
Re-operative thyroid surgery is technically challenging due to the formation of adhesions and
scar tissue, and is associated with increased rates of recurrent laryngeal nerve injury and
hypoparathyroidism  [119,120,121].  Operative  intervention  for  recurrence  accounts  for
anywhere between 5–12% of all thyroidectomies performed [122,123]. However, the last twenty
years have seen a shift away from conservative primary operations such as bilateral subtotal
thyroidectomy and this should begin to be mirrored by declining recurrence rates [124].
The risks associated with reoperation should be carefully examined and balanced with the
options of medical management or observation [119,120,121]. The extent of the disease should
be assessed in addition to the location and possible complications such as nerve injury and
excision of the parathyroid glands [124].
The operation of choice in all cases of recurrent nodular goiter should be a completion total
thyroidectomy. The surgical approach is dependent on the extent of the initial operation and
the size and location of the recurrent goitre. Re-operation following a subtotal or total thyroi‐
dectomy is hazardous and requires a methodical and standardized operative approach [124].
The key is the initial identification of anatomical landmarks outside the original operative field.
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The dissection must commence laterally by mobilization of the sternocleidomastoid muscle to
expose the carotid sheath. The carotid sheath may however be displaced medially and lie
abutting both fibrous tissue and the thyroid remnant. Dissection continues until the lateral
aspect of the gland in encountered. It is important to ensure that the nerve is not encased within
the strap muscles prior to their division. Identification of standard landmarks is vital. Therefore
the esophagus posteriorly and the trachea anteriorly should be identified next. This helps to
narrow down the location of the recurrent laryngeal nerve, which should be lying within the
trachea-oesophageal groove. Protection of the recurrent laryngeal nerve is best achieved by
identifying it in virgin territory. Dissection should thus begin low down in the trachea-
esophageal groove, if necessary as low as the thoracic inlet, where the nerve can be safely
identified in an undisturbed, non-operated field. Once the nerve has been identified, its course
is traced through to the insertion into the cricothyroid muscle. The recurrent laryngeal nerve
should not be sought at the fibrosed upper pole, as the risk of subsequent damage is extremely
high. Mobilization of the thyroid is by capsular dissection. Sub-sternal recurrent goitre may
increase the difficulty of surgical management and may be associated with a significantly
higher rate of recurrent laryngeal nerve damage as it exits the thoracic inlet. A sternal split is
rarely required. However, where there is excessive local bleeding or where removal of the
gland is prevented by excessive fibrosis a partial sternal split provides adequate access [124].
10.6. Retrosternal thyroid extension
Given the embryological descent of the thyroid most extension of the thyroid gland is into the
anterior and superior mediastinum. In the majority of cases the retrosternal component of the
thyroid gland can be delivered into the neck with gentle traction upwards given the position
the patient on the operation table [105]. In the small number of cases where the thyroid extends
behind the trachea and enters into the posterior mediastinum, there is a risk of injury to major
vessels and structures within the chest and a median sternotomy in conjunction with the
cardio-thoracic surgeons should be performed [105].
10.7. Postoperative care
Post operative patients are monitored closely for complications. Typically, thyroid surgery is
performed as a 23 hour surgical stay but increasingly in smaller cases there has been a move
to day case surgery. Patients are observed for exclusion of a post-operative haematoma and
subsequent airway compromise as well as for signs and symptoms of hypocalcemia in the
immediate post-operative period. Close monitoring of calcium levels especially in sympto‐
matic patients is crucial. Clinical tests of hypocalcaemic, including Chvostek’s sign (tapping
of facial nerve causing facial muscles to twitch) and Trousseu’s sign (finger and wrist spasm
on insufflation of a sphygnomanomator cuff around arm), may be present [125]. Studies have
shown that oral calcium and vitamin D supplementation has been found to decrease the
development of hypocalcaemic symptoms. However, a randomized trial that included 143
patients undergoing a total thyroidectomy, showed that patients with a PTH level >10 pg/mL
obtained on post-operative day one could be safely discharged without routine calcium
supplementation [126]. Calcium levels need to be followed up as hypercalcaemia may occur.
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In addition short term courses are usually sufficient and supplementation may be discontinued
once levels are normalised.
It is recommended that thyroid hormone is started on the first post-operative day in patients
who have undergone a total thyroidectomy. Serum TSH and free T4 are tested 6 weeks
postoperatively and the dose of oral thyroxine adjusted accordingly. Anti-thyroid medications
are stopped following surgery and beta-blockers may be weaned.
11. Complications of surgery
The most important complications of thyroid surgery include recurrent laryngeal nerve injury,
external superior laryngeal nerve injury, hypoparathyroidism, laryngeal oedema, bleeding,
hypothyroidism/hyperthyroidism, wound infection and keloid scarring. Morbidity from
thyroid surgery is minimised with meticulous anatomical dissection and operating in a
bloodless field.
11.1. Airway obstruction
This complication, although rare, remains life-threatening. This can be due to sub-glottic and
laryngeal oedema caused by venous and lymphatic obstruction, post-operative haematoma
formation or bilateral recurrent laryngeal nerve damage. The identification of early signs of
airway obstruction are crucial. It is recognised by a distressed patient and the presence of
increasing stridor. Immediate suture removal and exploration of the wound is warranted. If
no haematoma is demonstrated then one may proceed with conservative treatment with
humidified oxygen and the administration of intravenous glucocorticoids. Anaesthetic input
is recommended as intubation may be necessary to secure the patient’s airway [22].
11.2. Haemorrhage
Haemostasis is paramount in thyroid surgery. Bleeding from the thyroid arteries and veins or
the thyroid remnant can lead to the development of a haematoma deep to the strap muscles.
A haematoma requires immediate decompression by opening all the layers of the wound and
return to the operating room to control the underlying bleeding. The airway must be secured
and sometimes a definitive airway is required although intubation for 24 hours with use of
glucocorticoids and subsequent trial of extubation may save the patient a tracheostomy [22].
11.3. Nerve damage
Recurrent laryngeal nerve injury is rare and has been reported to occur 0.3-3% of cases
permanently [127]. The incidence is increased in recurrent thyroid surgery and total thyroi‐
dectomy compared with thyroid lobectomy. The nerve can be typically injured or divided
during ligation of the inferior thyroid artery or as it enters the larynx at the ligament of Berry.
Mobilisation of large goitres can also stretch the nerve and make it more vulnerable to damage
[10]. Paresis or partial damage of RLN, which is more common than complete transection,
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results in the vocal cord on the affected side adopting a midline adducted position [10].
Transient paresis of the RLN can occur with rates of 1.8% at one month and 0.5% at 3 months
for first time operations suggesting improvement with time [22]. Symptoms of unilateral RLN
damage include hoarseness, inability to speak loudly, fatiguable of the voice and an increased
risk of aspiration [128]. In bilateral RLN damage both cords adopt a midline position and
symptoms include total loss of voice, stridor and airway compromise requiring tracheostomy
[10]. Measures to reduce RLN injury include pre-operative laryngoscopy to assess vocal cord
function, direct identification of RLN and use of vocal cord stimulator intra-operatively.
The external branch of the superior laryngeal nerves lies close to the superior thyroid artery
and can be damaged as the vessels are ligated and divided. Damage to the SLN causes the
inability of the cricothyroid to tighten the vocal cords resulting in a weakness in phonation
and a change in pitch of the voice [10]. These findings are more subtle than damage to the RLN
and may be overlooked unless patients are specifically asked regarding symptoms [10].
Measures to avoid SLN injury include individually ligating the arterial branches close to the
thyroid gland and identifying the nerve where possible [22].
11.4. Hyperthyroidism / Hypothyroidism
Hypothyroidism occurs with total thyroidecomy. In thyroid lobectomy, the incidence of
hypothyroidism can be as high as 50% although the rate quoted is predominantly less than
this, typically 20% [129]. Port-operative monitoring and follow-up of thyroid function is
therefore needed. Hyperthyroidism, on the other hand, represents failure of the operation or
the presence of thyroid remnants left in situ at the time of the operation. This occurs in around
5% of patients. The three common site of embryological recurrence or persistence of nodular
goitre are within the pyramidal lobe, within thyroid rests in the thyrothymic tract or within
posterior remnants associated with the tubercle of Zuckerkandl (Figure 9).
11.5. Parathyroid insufficiency and hypocalcaemia
Inadvertent damage or removal of a parathyroid gland can result in either temporary or
permanent hypoparathyroidism post operatively. Careful identification of the parathyroid
glands and their preservation are crucial in order to avoid this complication as discussed above.
A study by Thomusch et al demonstrated transient hypoparathyroidism in 7.3% of patients
and permanent parathyroid dysfunction in 1.5% of patients [130]. Ionised calcium and PTH
levels should be measured immediately postoperatively, before discharge and at outpatient
review. Thomusch et al demonstrated a correlation between long term hypoparathyroidism
and the extent of initial surgery [130]. Further work within this group demonstrated other
significant factors for the development of hypoparathyroidism which included patient gender,
hospital operative volume, and Graves' disease [131].
The symptomatic outcome of hypoparathyroidism if either temporary or permanent hypo‐
calcemia [132]. Symptoms of hypocalcemia include paresthesia (especially circumorally and
in digits), cramps, carpopedal spasm, tetany and convulsions. Treatment is with calcium
supplementation orally or intravenously depending on degree of hypocalcemia and the
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presence of symptoms. Oral Vitamin D replacement can also be required. If calcium levels fail
to increase the serum magnesium should be assessed and replaced as required [132].
Surgeons should be aware of the possibility of thyrotoxic patients developing Hungry bone
syndrome post-operatively. As previously mentioned the presence of hyperthyroidism
increases bone turnover [133,134] Therefore similar to its pathogenesis in parathyroid bone
disease, removal of the excess thyroid hormone stimulation post thyroidectomy causes an
imbalance in bone formation-resorption leading to an increase uptake of calcium, phosphate
and magnesium in the osteoporotic bones [135,136] This leads to profound hypocalcemia,
hypophosphatemia and hypomagnesemia. Treatment is with careful monitoring and electro‐
lyte replacement [136].
Figure 9. Embryological development of the thyroid gland [118]
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11.6. Thyroid storm
This life-threatening condition is rarely seen post-operatively and is an acute exacerbation of
thyroitoxicosis with an associated adrenergic response [137]. It accounts for less than 1–2% of
all hospital admissions with hyperthyroidism but the mortality remains high at approximately
20–30% [138,139]. It typically occurs in patients who do not have an underlying diagnosis of
hyperthyroidism. The crisis has an abrupt onset and is almost always evoked by a precipitating
factor, such as infection, trauma, thyroidal surgery or radioactive iodine [3,16]. It is usually
documented in patients undergoing thyroid surgery without adequate pre-operative prepa‐
ration or where the diagnosis of thyrotoxicosis was not established [22]. Hormones released
as a result of thyroid gland manipulation result in acute post-operative thyrotoxicosis[140].
Patients in crisis present with fever, abdominal pain, vomiting, diarrhoea, psychosis, altered
mental state and coma. Signs include tachycardia, hypertension or hypotension, hyperpyrexia,
atrial fibrillation and signs of congestive heart failure [141]. Treatment is aimed at reducing
thyroid hormone secretion, supportive treatment and treatment of any underlying cause. It
includes immediate fluid resuscitation, cooling with ice packs, supplemental oxygen, intra‐
venous dextrose, diuretics and digoxin [22]. Specific treatments include intravenous beta
blockers, propylthiouracil, potassium iodide and high dose steroids. Ensuring adequate and
meticulous pre-operative preparation of patients should prevent this situation.
11.7. Tracheomalacia
Tracheomalacia represents a rare entity that is not completely understood. This condition is
postulated to occur secondary to longstanding extrinsic tracheal compression with subsequent
loss of tracheal cartilage rigidity, culminating in dynamic airway collapse in excess of 50% of
diameter [142]. The typical manifestation of post-operative tracheomalacia is acute respiratory
distress following extubation not explained by any other cause. This necessitates prompt re-
intubation or a tracheostomy and the addition of high doses of glucocorticoids. A number of
series failed to show cases of tracheomalacia [143,144], while a small number has been reported
in others [145]. It has been postulated that this entity has been mistaken for unrecognised
bilateral vocal cord paralysis [146]. Tracheomalacia is treated with intubation, tracheotomy,
mesh repair of the posterior tracheal wall, trachelopexy and grafting.
12. Conclusion
Hyperthyroidism occurs as a result of an increase in thyroid hormone synthesis and secretion
by the thyroid gland. This most commonly manifests as Graves’ disease, multi-nodular goitre
or a solitary toxic nodule. The management of hyperthyroidism is based on three treatment
modalities, namely anti-thyroid medication, radioactive iodine ablation or surgery. Surgery
increasingly plays an important role in the management of benign thyroid disease and has
evolved into a cost-effective treatment with minimal associated morbidity and mortality. Total
thyroidectomy is the surgery of choice in Graves’ disease, while a total thyroidectomy or
thyroid lobectomy are utilised in patients with toxic nodular goitres and this choice is dictated
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by the disease site and extent. Although thyroid surgery can be associated with significant
complications, in high volume operative centres surgery provides effective long-lasting
resolution of hyperthyroidism and therefore should be considered an integral component of
treatment rather than the last resort of clinicians
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